Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Mark Vickery headshot

Best Single Trading Day in Months for Dow, Nasdaq, S&P

by Mark Vickery

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

by Zacks Equity Research

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.

Mark Vickery headshot

Pre-Markets Back to Green Ahead of Economic & Earnings Data

by Mark Vickery

After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.

Markets Await Economic and Earnings Data

by Zacks Equity Research

Markets Await Economic and Earnings Data

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $305.10, marking a +0.06% move from the previous day.

Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQQE

Neena Mishra headshot

With IPOs Red Hot, What's Next for ETFs?

by Neena Mishra

2021 is another blockbuster year for IPOs, here is what investors should know.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose

by Zacks Equity Research

Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.

J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab

by Zacks Equity Research

J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.

Ekta Bagri headshot

Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion

by Ekta Bagri

Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $332.11, marking a +1.92% move from the previous day.

Why Moderna (MRNA) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

Daniel Laboe headshot

Market Bears Take The Bulls By The Horns As Q4 Kicks Off

by Daniel Laboe

We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

by Zacks Equity Research

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth

by Zacks Equity Research

In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

Gilead (GILD) Tecartus Gets FDA Nod for Leukemia Indication

by Zacks Equity Research

Following FDA approval, Gilead's (GILD) Tecartus becomes the first and only CAR T-cell therapy approved for treating relapsed/refractory B-cell acute lymphoblastic leukemia in adult patients.

Sweta Jaiswal, FRM headshot

Take a Look at the Top-Performing Biotech ETFs YTD

by Sweta Jaiswal, FRM

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

by Zacks Equity Research

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.